Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ionis AGT-LRx · 1 trial · 1 indication
The safety and tolerability of single and multiple doses of IONIS AGT-LRx will be assessed by determining the incidence, severity, and dose relationship of adverse events that are related to treatment with IONIS AGT-LRx
The safety and tolerability of single and multiple doses of IONIS AGT-LRx will be assessed by reviewing any observed changes in Blood Pressure measurements, physical exam, and laboratory tests from baseline by dose. Results in subjects dosed with IONIS AGT-LRx will be compared with those from subjects dosed with placebo.
| Arm | Type | Description |
|---|---|---|
| Ionis AGT-LRx | EXPERIMENTAL | Ascending single and multiple doses of Ionis AGT-LRx administered subcutaneously. |
| Placebo | PLACEBO_COMPARATOR | Saline .9% |
| Name | Type | Description |
|---|---|---|
| Ionis AGT-LRx | DRUG | Ascending single and multiple doses of Ionis AGT-LRx administered subcutaneously |
| Placebo | DRUG | Saline .9% |
Inclusion Criteria: * Must have given written informed consent and be able to comply with all study requirements * Healthy males or females aged 18-60 inclusive and weighing ≥ 50 kg at the time of Informed Consent * Females must be non-pregnant and non-lactating, and either surgically sterile or po...
IONIS-AGT-LRx is an investigational drug being studied for hypertension and chronic heart failure with reduced ejection fraction. It has been evaluated in clinical trials involving healthy volunteers, hypertensive participants with uncontrolled blood pressure, and participants with chronic heart failure with reduced ejection fraction. The drug is in Phase 2 development for these cardiovascular conditions.
IONIS-AGT-LRx targets angiotensinogen, a protein involved in blood pressure regulation. By reducing angiotensinogen levels, the drug aims to lower blood pressure. This mechanism is being investigated as a potential treatment for hypertension and chronic heart failure with reduced ejection fraction.
IONIS-AGT-LRx is developed by Ionis Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol IONS. The company is conducting clinical trials to evaluate the drug's safety, tolerability, and efficacy in cardiovascular conditions.
IONIS-AGT-LRx is in Phase 2 clinical development. It has completed Phase 1 and Phase 2 trials, including studies in healthy volunteers, hypertensive participants, and participants with chronic heart failure with reduced ejection fraction. The drug is investigational and not yet approved by regulatory authorities.
IONIS-AGT-LRx has been studied in three completed clinical trials. NCT03101878 was a Phase 1 study in healthy volunteers. NCT04714320 was a Phase 2 study in hypertensive participants with uncontrolled blood pressure. NCT04836182 was a Phase 2 study in participants with chronic heart failure with reduced ejection fraction.
Yes, IONIS-AGT-LRx is also referred to as Ionis AGT-LRx. The drug is developed by Ionis Pharmaceuticals and has been studied under both names in clinical trials. It targets angiotensinogen for the treatment of hypertension and chronic heart failure with reduced ejection fraction.